Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Bradford D Wilson

Bradford D Wilson

Howard University,USA

Title: Clinical Pharmacogenetics of CYP3A4 in MAT for OUD: a case for diversity

Biography

Biography: Bradford D Wilson

Abstract

Opioid use disorder (OUD) and the associated increase in overdose deaths has become a U.S. national health priority. Medication-assisted therapy (MAT) is a treatment approach commonly used in OUD management. Buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, has been shown to be an effective MAT option for OUD management. Buprenorphine is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. The CYP3A4*1B allele confers an ultrarapid metabolizer phenotype and is found at a significantly higher frequency in African populations compared to non-African populations. This genetic difference in CYP3A4 metabolism leaves some patients being managed on buprenorphine undertreated and at an increased risk for relapse. Clinical pharmacogenomics (CPGx) testing of CYP3A4 has been shown to improve MAT outcomes in African American patients. PGx-guided buprenorphine dosing reduced the number of relapses on OUD patients exhibiting the CYP3A4*1B genotype. Reduced relapse translates into additional downstream benefits including reduction in risk of Hepatitis C and/or HIV infection. The functional significance and clinical utility of this variant demonstrate the need for diversity in CPGx studies and pharmacogenomics testing algorithms.

Recent Publications:

  1. Opioid Metabolizing Enzyme Allele Frequencies and Drug use in a Cohort of African American Young Adults. Bradford D. Wilson, Earl B. Ettienne, Victor Apprey, Adaku Ofeogbu, Muneer Abbas, Georgia M. Dunston, Forough Saadatmand ARC Journal of Addiction 2017 2: 4-9
  2. Public choice theory and rhetoric: Advancing pharmacogenomics through health policy in Africa. Earl Ettienne, LP.D., MBA, RPh, Adaku Ofoegbu, PharmD, Mary Maneno, PhD, La’Marcus Wingate, PhD, Georgia Dunston, PhD, Philip Kurian, PhD, Bradford D. Wilson, PhD, KevinNguyen, Ginikannwa Ezeude, Jeronimo Augusto, MHSA African Journal of Rhetoric 2017 9: 119-142
  3. Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach. Earl B. Ettienne, Edwin Chapman, Mary Maneno, Adaku Ofoegbu, Bradford Wilson, Beverlyn Settles-Reaves, Melissa Clarke, Georgia Dunston, Kevin Rosenblatt. Addictive Behaviors Reports 2017 Dec; 6: 8–14
  4. Next generation sequencing reveals high prevalence of BRCA1 and BRCA2 variants of unknown significance in early-onset breast cancer in African American women. Luisel J Ricks-Santi, PhD; John Tyson McDonald, PhD; Bert Gold, PhD; Michael Dean, PhD; Nicole Thompson, MS; Muneer Abbas, PhD; Bradford Wilson, PhD; Yasmine Kanaan, PhD; Georgia Dunston, PhD. Ethnicity and Disease. 2017 Apr 20:27(2):169-178
  5. Genetic polymorphisms in the serotonin receptor 7 (HTR7) gene are associated with cortisol levels in African American young adults. G Swanson, S Miller, A Alyahyawi, B Wilson, F Saadatmand, C Lee, G Dunston, M Abbas. F1000 Research 6:19 · January 2017